Name of NDs | Antigen | Type of radiolabeling | Type of study | The mechanism of action | References |
---|---|---|---|---|---|
Iso-[131I]SGMIB-VHH-1028 | HER2 | Iso-[131I] SGMIB | Pre-clinical/ Balb/c mice bearing BT474 tumor cells | Prevent tumor progression | |
Iso-211At-SAGMB-5F7 | HER2 | Iso-211At-SAGMB | Pre-clinical/ Balb/c mice bearing BT474 tumor cells | Tumor regression | |
125I-VHH 131I- IB-Mal-D-GEEEK-VHH | HER2 HER2 | Iodine125 IB-Mal-D-GEEEK/Iodine 131 | Pre-clinical/ Balb/c mice bearing BT474 tumor cells | Using in radio-immunotherapy and SPECT and PET imaging of HER2 + tumors | |
225Ac-DOTA- 2Rs15d VHH | HER2 | p-SCN-Bn-DOTA/α- irradiators 225Ac | Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells | Using in radio-immunotherapy in HER2 + tumors | |
225Ac DOTA 2Rs15d | HER2 | 225Ac | Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells | Strong and targeted tumor uptake in both HER2 positive brain lesions | Puttemans et al. [77] |
18F-FB-anti-HER2 | HER2 | 4-[18F] fluorobenzoate ([18F]-SFB) | Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells | A radiometal labeled nbs when imaging lesions in the proximity of the kidneys | |
Iso-211At-SAGMB-5F7 | HER2 | Iso-[211At]SAGMB | Pre-clinical/ Balb/c mice bearing BT474 tumor cells | Targeted radiotherapeutics for the treatment of HER2 expressing malignancies | Choi et al. [79] |
177Lu-1B4M–DTPA-2Rs15dHIS | HER2 | 177Lu-1B4M–DTPA | Pre-clinical/ Balb/c mice bearing SKOV3 tumor cells | Radiolanthanide Lutetium-177 emit radiation with an appropriate linear energy transfer for the destruction of tumor cells | |
99mTc-2Rs15d | HER2 | Technetium-99m | Phase I clinical trial (NCT04040686) | HER2-positive tumor imaging | Devoogdt et al. [82] |
68Ga-NOTA-2Rs15d | HER2 | Gallium 68 | Phase I clinical trial (EudraCT 012001135-31) A second phase II clinical trial (VUBAR) | A safe HER2-positive tumor imaging used as PET radiotracers | Keyaerts et al. [83] |
131I-NM-02 | HER2 | Iodine 131 | Pre-clinical/ Balb/c mice bearing SKBR3 tumor cells | A novel technique for targeted radionuclide therapy of HER2-positive breast cancer | |
131I-SGMIB-2Rs15d | HER2 | Iodine 131 | Phase I clinical trial (NCT02683083) A follow-up phase I/II clinical trial (NCT04467515) | Therapeutic potential for patients who progress on trastuzumab, pertuzumab, or trastuzumab emtansine |